Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 2
1956 1
1957 1
1962 1
1964 1
1967 1
1971 2
1972 1
1978 1
1981 1
1982 1
1985 2
1986 5
1987 5
1988 4
1989 3
1990 5
1991 8
1992 6
1993 7
1994 12
1995 11
1996 9
1997 6
1998 12
1999 22
2000 8
2001 15
2002 21
2003 22
2004 11
2005 24
2006 16
2007 24
2008 22
2009 59
2010 52
2011 50
2012 36
2013 35
2014 43
2015 55
2016 58
2017 64
2018 65
2019 53
2020 49
2021 53
2022 30
2023 57
2024 80
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

994 results

Results by year

Filters applied: . Clear all
Page 1
VISTA is an acidic pH-selective ligand for PSGL-1.
Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, Corbett M, Rankin AL, Dibella R, Campbell L, Martin GH, Lemar H, Cayton T, Huang RY, Deng X, Nayeem A, Chen H, Ergel B, Rizzo JM, Yamniuk AP, Dutta S, Ngo J, Shorts AO, Ramakrishnan R, Kozhich A, Holloway J, Fang H, Wang YK, Yang Z, Thiam K, Rakestraw G, Rajpal A, Sheppard P, Quigley M, Bahjat KS, Korman AJ. Johnston RJ, et al. Among authors: rizzo jm. Nature. 2019 Oct;574(7779):565-570. doi: 10.1038/s41586-019-1674-5. Epub 2019 Oct 23. Nature. 2019. PMID: 31645726
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Hodi FS, et al. Among authors: rizzo j. Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Lancet Oncol. 2018. PMID: 30361170 Clinical Trial.
Atypical Optic Neuritis.
Gaier ED, Boudreault K, Rizzo JF 3rd, Falardeau J, Cestari DM. Gaier ED, et al. Among authors: rizzo jf 3rd. Curr Neurol Neurosci Rep. 2015 Dec;15(12):76. doi: 10.1007/s11910-015-0598-1. Curr Neurol Neurosci Rep. 2015. PMID: 26467052 Review.
Polycationic glycosides.
Engel R, Ghani I, Montenegro D, Thomas M, Klaritch-Vrana B, Castaño A, Friedman L, Leb J, Rothman L, Lee H, Capodiferro C, Ambinder D, Cere E, Awad C, Sheikh F, Rizzo J, Nesbitt LM, Testani E, Melkonian K. Engel R, et al. Among authors: rizzo j. Molecules. 2011 Feb 11;16(2):1508-18. doi: 10.3390/molecules16021508. Molecules. 2011. PMID: 21317841 Free PMC article.
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF, Schreiber S, D'Haens G, Rizzo J, Kligys K, Griffith J, Zambrano J, Zhou Q, Zhang Y, Kalabic J, Rieder F, Dubinsky MC, Panaccione R. Colombel JF, et al. Among authors: rizzo j. J Crohns Colitis. 2024 Jun 3;18(6):818-827. doi: 10.1093/ecco-jcc/jjad206. J Crohns Colitis. 2024. PMID: 38069472 Free PMC article. Clinical Trial.
Ophthalmic manifestations of giant cell arteritis.
Vodopivec I, Rizzo JF 3rd. Vodopivec I, et al. Among authors: rizzo jf 3rd. Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii63-ii72. doi: 10.1093/rheumatology/kex428. Rheumatology (Oxford). 2018. PMID: 29986083 Review.
994 results